Aclaris Therapeutics Inc logo

Aclaris Therapeutics Inc (8AT)

Market Open
3 Apr, 14:32
1. 38
-0.05
-3.39%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-1.64 Eps
1.429
Previous Close
Day Range
1.35 1.38
Year Range
0.9 4.51
Earnings results expected in 64 days

Summary

8AT trading today lower at €1.38, a decrease of -3.39% from yesterday's close, completing a monthly decrease of -27.21% or €0.52. Over the past 12 months, 8AT stock lost -41.86%.
8AT is not paying dividends to its shareholders.
The last earnings report, released on Feb 25, 2025, missed the consensus estimates by -0.64%. On average, the company has fell short of earnings expectations by -0.23%, based on the last three reports. The next scheduled earnings report is due on Jun 06, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track 8AT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

8AT Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

Aclaris Therapeutics Inc Dividends

8AT is not paying dividends to its shareholders.

Aclaris Therapeutics Inc Earnings

6 Jun 2025 (64 Days) Date
-
Cons. EPS
-
EPS
25 Feb 2025 Date
-
Cons. EPS
-
EPS
4 Nov 2024 Date
-
Cons. EPS
-
EPS
7 Aug 2024 Date
-
Cons. EPS
-
EPS
5 Aug 2024 Date
-
Cons. EPS
-
EPS
8AT is not paying dividends to its shareholders.
6 Jun 2025 (64 Days) Date
-
Cons. EPS
-
EPS
25 Feb 2025 Date
-
Cons. EPS
-
EPS
4 Nov 2024 Date
-
Cons. EPS
-
EPS
7 Aug 2024 Date
-
Cons. EPS
-
EPS
5 Aug 2024 Date
-
Cons. EPS
-
EPS

Aclaris Therapeutics Inc (8AT) FAQ

What is the stock price today?

The current price is €1.38.

On which exchange is it traded?

Aclaris Therapeutics Inc is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is 8AT.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is -0.29.

When is the next earnings date?

The next earnings report will release on Jun 06, 2025.

Has Aclaris Therapeutics Inc ever had a stock split?

No, there has never been a stock split.

Aclaris Therapeutics Inc Profile

Diagnostics & Research Industry
Healthcare Sector
Dr. Neal S. Walker D.O., M.D. CEO
XDUS Exchange
US00461U1051 ISIN
United States Country
86 Employees
- Last Dividend
- Last Split
7 Oct 2015 IPO Date

Overview

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel treatments for immune-inflammatory diseases. The company, founded in 2012 and based in Wayne, Pennsylvania, operates within the United States across two main segments: Therapeutics and Contract Research. The Therapeutics segment is focused on identifying and developing innovative therapies aimed at meeting the significant unmet needs in immuno-inflammatory diseases. Meanwhile, the Contract Research segment offers laboratory services, supporting the broader research and development efforts within the field.

Products and Services

  • Zunsemetinib (ATI-450)

    An MK2 inhibitor currently under Phase 1b/2 trials designed for the treatment of metastatic breast and pancreatic cancer. Zunsemetinib aims to address critical gaps in the treatment of these widespread and deadly cancers by targeting and inhibiting specific molecular pathways associated with tumor growth and spread.

  • ATI-1777

    A soft JAK 1/3 inhibitor that has completed Phase 2b trials for the treatment of moderate to severe atopic dermatitis, among other dermatologic conditions. ATI-1777 represents a novel approach in managing dermatologic conditions by modulating the immune response, potentially offering a therapeutic alternative for patients with limited treatment options.

  • ATI-2138

    An oral covalent inhibitor of ITK and JAK3, currently under Phase 1 trials as a potential treatment for T cell-mediated autoimmune diseases. ATI-2138 works by inhibiting specific enzymes involved in the activation of T cells, part of the immune system's response that can cause harmful inflammation in autoimmune diseases.

Contact Information

Address: 701 Lee Road
Phone: 484 324 7933